Serina Therapeutics, Inc. — Director's Dealing 2021

Mar 16, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AgeX Therapeutics, Inc. (AGE)
CIK: 0001708599
Period of Report: 2021-03-11

Reporting Person: WEST MICHAEL D (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-11	Common Stock, $0.0001 par value	M	3125	$0.00	Acquired	33723	Direct
2021-03-11	Common Stock, $0.0001 par value	F	1284	$2.03	Disposed	32439	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-03-11	Restricted Stock Units	$0.00	M	3125	Disposed		Common Stock (3125)	Direct

Footnotes

F1: Securities withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 3,125 Restricted Stock Units, the grant of which was previously reported on a Form 4.

F2: Restricted Stock Units vested on March 11, 2021.